Filing Details

Accession Number:
0001209191-22-045114
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-08-09 19:54:51
Reporting Period:
2022-08-05
Accepted Time:
2022-08-09 19:54:51
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1029142 Dynavax Technologies Corp DVAX Pharmaceutical Preparations (2834) 330728374
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1580849 Robert Janssen C/O Dynavax Technologies
2100 Powell Street, Suite 720
Emeryville CA 94608
Senior Vice President No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-08-05 900 $10.47 25,607 No 4 M Direct
Common Stock Disposition 2022-08-05 900 $17.01 24,707 No 4 S Direct
Common Stock Acquisiton 2022-08-08 4,450 $10.47 29,157 No 4 M Direct
Common Stock Disposition 2022-08-08 4,450 $17.16 24,707 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2022-08-05 900 $0.00 900 $10.47
Common Stock Stock Option (Right to Buy) Disposition 2022-08-08 4,450 $0.00 4,450 $10.47
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
12,795 2026-02-21 No 4 M Direct
8,345 2026-02-21 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 15, 2021.
  2. This transaction was executed in multiple trades at prices ranging from $17.00 to $17.07; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
  3. This transaction was executed in multiple trades at prices ranging from $17.00 to $17.43; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
  4. This option grant will vest over three (3) years with one-third (1/3) of the shares subject to the option vesting twelve months after the grant date, and one thirty-sixth (1/36) of the shares subject to the option vesting on the last day of each month thereafter.
  5. Not applicable.